OPKO Health’s (OPK) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $3.00 price target on the biotechnology company’s stock.

A number of other research firms also recently commented on OPK. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Trading Down 0.7 %

NASDAQ OPK opened at $1.47 on Wednesday. The company’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $1.50. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63. OPKO Health has a 12 month low of $0.86 and a 12 month high of $1.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 280,183 shares of the business’s stock in a transaction on Friday, November 8th. The shares were purchased at an average price of $1.50 per share, with a total value of $420,274.50. Following the purchase, the chief executive officer now directly owns 211,512,405 shares of the company’s stock, valued at approximately $317,268,607.50. The trade was a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have purchased 1,304,255 shares of company stock valued at $2,024,605 over the last three months. Company insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. CIBC Asset Management Inc increased its stake in OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 8,978 shares during the period. FMR LLC increased its stake in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the period. Algert Global LLC acquired a new stake in OPKO Health in the second quarter worth approximately $44,000. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health in the third quarter worth approximately $45,000. Finally, Private Advisor Group LLC boosted its stake in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.